We have previously shown in a BRAFV600E glioma model that BRAF monotherapy is inefficient in suppressing tumor growth, whereas combination with EGFR inhibitor confers significant anti-tumor efficacy, suggesting that both BRAF oncogene as well as primary resistance mechanisms have to be inhibited in vivo to prevent acute resistance from developing [9]. This evidence concerns the gene EGFR and central nervous system cancer.